[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Newamsterdam Pharma Company N.V. (NAMS)

Newamsterdam Pharma Company N.V. (NAMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,553,881
  • Shares Outstanding, K 116,904
  • Annual Sales, $ 22,500 K
  • Annual Income, $ -203,820 K
  • EBIT $ -215 M
  • EBITDA $ -215 M
  • 60-Month Beta 0.07
  • Price/Sales 157.20
  • Price/Cash Flow N/A
  • Price/Book 5.32

Options Overview Details

View History
  • Implied Volatility 64.07% (-2.75%)
  • Historical Volatility 64.47%
  • IV Percentile 10%
  • IV Rank 11.62%
  • IV High 137.17% on 09/15/25
  • IV Low 54.46% on 01/20/26
  • Expected Move (DTE 3) 1.11 (3.64%)
  • Put/Call Vol Ratio 0.20
  • Today's Volume 12
  • Volume Avg (30-Day) 747
  • Put/Call OI Ratio 3.00
  • Today's Open Interest 18,269
  • Open Int (30-Day) 16,957
  • Expected Range 29.49 to 31.71

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.48
  • Number of Estimates 4
  • High Estimate $-0.36
  • Low Estimate $-0.54
  • Prior Year $-0.15
  • Growth Rate Est. (year over year) -220.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.13 +5.05%
on 06/11/26
37.34 -18.05%
on 05/27/26
-4.84 (-13.66%)
since 05/15/26
3-Month
27.85 +9.87%
on 04/28/26
42.21 -27.50%
on 05/11/26
+1.98 (+6.92%)
since 03/13/26
52-Week
17.63 +73.57%
on 06/23/25
42.21 -27.50%
on 05/11/26
+10.39 (+51.41%)
since 06/13/25

Most Recent Stories

More News
NewAmsterdam Pharma Sets PREVAIL Interim Analysis for Q4 2026 on Encouraging Blinded Trends

NewAmsterdam Pharma (NASDAQ:NAMS) said it plans to conduct an interim analysis of its ongoing PREVAIL cardiovascular outcomes trial (CVOT) for obicetrapib in the fourth quarter of 2026, citing what executives...

NAMS : 30.60 (+0.66%)
Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site

/CNW/ -- Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA)...

NAMS : 30.60 (+0.66%)
Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg

– Both pivotal studies achieved primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies with high statistical...

NAMS : 30.60 (+0.66%)
NewAmsterdam Pharma Closes $452.6 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NewAmsterdam Pharma closes a public offering, raising approximately $452.6 million for its LDL-C lowering therapies.Quiver AI SummaryNewAmsterdam Pharma Company N.V. has completed its underwritten public...

NAMS : 30.60 (+0.66%)
NewAmsterdam Pharma Prices $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NewAmsterdam Pharma announces $416.5 million public offering of ordinary shares and pre-funded warrants to support cardiovascular treatments.Quiver AI SummaryNewAmsterdam Pharma Company N.V., a clinical...

NAMS : 30.60 (+0.66%)
NewAmsterdam Pharma Reports Positive Phase 3 Results for Obicetrapib in Lowering LDL-C and Reducing Cardiovascular Events

NewAmsterdam reports positive Phase 3 results for obicetrapib, showing significant LDL-C reduction and favorable safety profile compared to placebo.Quiver AI SummaryNewAmsterdam Pharma Company has reported...

NAMS : 30.60 (+0.66%)
NewAmsterdam Pharma Grants Inducement Share Options to New Non-Executive Hires

NewAmsterdam Pharma grants 79,000 share options to new hires as employment inducement under its 2024 Inducement Plan.Quiver AI SummaryNewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical firm...

NAMS : 30.60 (+0.66%)
NewAmsterdam Pharma Reports Significant Efficacy and Safety Results in Phase 3 BROOKLYN Trial of Obicetrapib for Heterozygous Familial Hypercholesterolemia

NewAmsterdam Pharma reports significant LDL-C and Lp(a) reductions with obicetrapib in Phase 3 trial, maintaining safety comparable to placebo.Quiver AI SummaryNewAmsterdam Pharma Company announced positive...

NAMS : 30.60 (+0.66%)
Why Shares of NewAmsterdam Pharma Were Plummeting on Wednesday

The company announced a stock sale to help fund operations.

NAMS : 30.60 (+0.66%)
EQT Life Sciences closes Dementia Fund at the hard cap

The LSP Dementia Fund has held its final close at approximately EUR 260 million, at the hard cap and above its original target fund size of EUR 100 million...

NAMS : 30.60 (+0.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

NewAmsterdam Pharma Holding B.V. is a late clinical-stage company focused on the research and development of transformative oral therapies for major cardiometabolic diseases. NewAmsterdam Pharma Holding B.V., formerly known as Frazier Lifesciences Acquisition Corporation, is based in MENLO PARK, Calif....

See More

Key Turning Points

3rd Resistance Point 32.27
2nd Resistance Point 31.87
1st Resistance Point 31.24
Last Price 30.60
1st Support Level 30.21
2nd Support Level 29.81
3rd Support Level 29.18

See More

52-Week High 42.21
Fibonacci 61.8% 32.82
Last Price 30.60
Fibonacci 50% 29.92
Fibonacci 38.2% 27.02
52-Week Low 17.63

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.